Background Recent studies have suggested that the association between smoking and breast cancer risk might be modified by polymorphisms in the N-acetyltransferase 2 gene (NAT2 
Materials and methods

Subjects
A multicenter population-based case-control study was conducted between December 2010 and November 2011 in Japan. The cases were consecutive patients with noninvasive or invasive breast cancer aged over 20 years who were treated at Okayama University Hospital, Okayama Rousai Hospital and Mizushima Kyodo Hospital in Okayama, and at Kagawa Prefecture Central Hospital in Kagawa. The controls were women aged over 20 years without a history of breast cancer who underwent breast cancer screening at Mizushima Kyodo Hospital in Okayama and at Kagawa Prefectural Cancer Detection Center in Kagawa. All subjects gave written informed consent before enrollment in the study. A blood sample (5 ml) was collected from each subject to use for single nucleotide polymorphism (SNP) analysis. Subjects were also given questionnaires that they completed at home and mailed back to Okayama University Hospital. The study was approved by the institutional ethics committee on human research at Okayama University.
The questionnaires collected information on age, height, body weight, smoking history, alcohol intake, habitual exercise, menstruation status, age at menarche, age at first full term pregnancy, number of children, breastfeeding, age at menopause, history of hormone replacement therapy, history of oral contraceptive use, history of benign breast disease, familial history of breast cancer (including mother, sisters and daughters). Smoking data included the amount of daily smoking (cigarettes/day), the duration of smoking (in years), and the time since cessation of smoking (in years). Body mass index (BMI) was calculated as body weight/square of height.
Selection of SNPs
To distinguish NAT2*5, NAT2*6 and NAT2*7, which are slow acetylator alleles, from NAT2*4, a rapid acetylator allele [4] , three SNPs (T341C, G590A, G857A) were analyzed, as in Cox et al. [3] . NAT2*14 is also a slow acetylator allele, but its allele frequency is very low, except in the African population [5] . Therefore, we did not check for NAT2*14 in this study.
SNP genotyping
Genomic DNA was isolated from whole blood with a TaqMan Ò Sample-to-SNP TM kit (Applied Biosystems, Foster City, CA, USA). Samples were analyzed by a TaqMan genotyping assay using the StepOne TM real-time polymerase chain reaction (PCR) system (Applied Biosystems), in a 96-well plate that included four blank wells as negative controls. The PCR consisted of an initial denaturation step at 95°C for 20 s, followed by 40 cycles at 95°C for 3 s, and 60°C for 20 s. PCR products were analyzed by StepOne TM Software ver. 2.3 (Applied Biosystems). To assess the quality of genotyping, we conducted re-genotyping of a randomly selected 5 % of samples and obtained 100 % agreement.
Definition of the NAT2 acetylation phenotype
Subjects homozygous for slow acetylator alleles were classified as a slow acetylator phenotype, and those who were carriers of at least one rapid acetylator allele were classified as a rapid acetylator phenotype, consistent with the definition in previous studies [2, 3] . In accordance with the Hardy-Weinberg equilibrium, analysis of SNPs was checked using a Chi squared test.
Statistical analysis
Unconditional logistic regression analysis was used to estimate odds ratio (OR) and 95 %CI for breast cancer risk with smoking status (never/former/current). Two models were used, with the first adjusted only for age (continuous), and the second adjusted for age (continuous) [3, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , body mass index (continuous) [3, 6, 7, 10, 11, 15] , number of children (continuous) [3, 7, 8, 10, 11, 14, 15] , menopausal status (pre/postmenopausal) [10, 11, 13] , family history of breast cancer (yes/no) [6-11, 14, 15] , and habitual drinking (never/at some time) [8, 10, 11, 14] . Subjects were excluded from the logistic regression if any of the adjusting covariates were missing. Age at menopause and age at first full term pregnancy were excluded as covariates for the second model analysis due to a number of missing values. Durations of cigarette smoking and pack-years of smoking were calculated from data collected by questionnaire. Factors were analyzed as both categorical and continuous variables. Smoking duration was stratified into \15 and C15 years, and pack-years into \20 and C20, as in Ambrosone et al. [2] . All data were also analyzed after stratification by menopausal status and NAT2 phenotype. Interactions between NAT2 phenotype and smoking were calculated by including the multiplicative terms in the models and evaluated by likelihood ratio test. All analyses were performed in Statistical Analysis System JMP ver. 11.0.0. (SAS Institute), with significance defined as p \ 0.05.
Results
A total of 515 patients with breast cancer cases and 528 healthy controls agreed to participate in the study and gave written informed consent. Among these subjects, 1 case and 1 control withdrew consent, and blood samples could not be obtained in 3 cases. Thus, 511 cases and 527 controls were included in the analyses. 51 cases and 32 controls never returned self-administered questionnaires, and some cases were complemented information by their medical records. Baseline characteristics and potential risk factors for breast cancer are shown in Table 1 . Cases were older than controls (mean age ± standard deviation (SD): 55.0 ± 12.3 vs. 52.7 ± 11.0 years, p = 0.002 by Student t test). Age, height, age at menarche, number of children, history of oral contraceptive use, and habitual exercise showed significant differences between cases and controls in an unadjusted model.
Frequencies of NAT2 genotypes are shown in Table 2 . The NAT2 genotype frequencies in controls conformed to the Hardy-Weinberg equilibrium (T341C, p = 1; G590A, p = 0.08; G857A, p = 0.5 by Chi-squared test). The NAT2 slow acetylator phenotype accounted for 11 % of cases and 10 % of controls, and was not associated with a significantly increased risk of breast cancer compared to the rapid acetylator phenotype (OR 1.15, 95 % CI 0.77-1.71). The mean age at menarche for the slow acetylator phenotype was older than that for the rapid acetylator phenotype (13.60 ± 0.15 vs. Table 1 did not differ significantly between the rapid and slow acetylator phenotypes (data not shown). Breast cancer risk associated with smoking history is shown in Table 3 . Compared to never smokers, current smokers had an increased breast cancer risk in multivariate analysis (OR 2.27, 95 % CI 1.38-3.82).
Subgroup analyses of menopausal status were shown in Table 4 . Regardless of menopausal status, there were roughly same tendencies seen in the analyses of total study population, except for former smoker in postmenopausal group. Compared to never smokers, former smokers were associated with lower risk of breast cancer (OR 0.41, 95 % CI 0.16-0.94).
In the rapid acetylator phenotype subgroup analysis shown in Table 5 , current smokers had a similar increased breast cancer risk (OR 2.36, 95 % CI 1.41-4.03), but in the slow acetylator phenotype subgroup, there was a very wide confidence interval and no significant difference between current smokers and never smokers (OR 2.60, 95 % CI 0.31-54.1). No interactions were observed between smoking status and NAT2 phenotype (p = 0.97).
In analyses of the dose-dependent effect of smoking on breast cancer risk, only the heavy smoker group differed significantly compared to never smokers. The OR for smoking for [15 years was 1.65 (95 % CI 1.03-2.67) and that for smoking for [20 pack-years was 2.48 (95 % CI 1.21-5.37). Differences between light smokers and never smokers were not significant ( Table 3 ). The same tendencies were found for the rapid acetylator phenotype (OR 1.65, 95 % CI 1.01-2.72; OR 2.42, 95 % CI 1.17-5.30, respectively, shown in Table 5 ). For the slow acetylator phenotype, all data had very wide confidence intervals and no significance.
In analyses of continuous variables, weak associations were observed between smoking extent and breast cancer risk (Table 3 ). The OR for each additional year of smoking was 1.02 (95 % CI 1.01-1.04) and that for each additional pack-year was 1.03 (95 % CI 1.01-1.06). In subgroup analyses, the rapid acetylator phenotype showed almost the same results, but there were no significant associations for the slow acetylator phenotype.
Discussion
This study showed a significant association between breast cancer and smoking. Compared to never smoker, current smoker had a significantly increasing risk with breast cancer. And, doseresponse relationship was observed between the risk and smoking dosage. These tendencies were consistent regardless of menopausal status and NAT2 phenotype.
Compared with previous studies [2, 3] , we obtained two important findings. First, there is a difference in the In analyses of categorical variables, the never smoker group was used as a reference group c In analyses of continuous variables, ORs and 95 % CIs were calculated for each additional year of smoking or for each additional pack-year Table 4 Smoking history and breast cancer risk stratified by menopausal status [4] . These data are consistent with the phenotype distributions in the current study and previous studies [2, 3] . The second finding in this study was a significant association of breast cancer risk and smoking for the rapid acetylator phenotype. Studies in Western countries [2, 3] are inconsistent with regard to the increase in breast cancer risk attributed to smoking among subjects with a rapid acetylator phenotype, but did show a consistent risk for the slow acetylator phenotype. Based on these studies [2, 3] , a larger sample size for the slow acetylator phenotype in our study may also have produced a positive association between breast cancer risk and smoking.
However, almost no association was observed for the slow acetylator phenotype. This might be because of small sample size of slow acetylator phenotype. This is one of the limitations in the study.
A second limitation is the hospital-based case-control study design, in which we cannot rule out selection bias associated with cancer screening. Breast cancer screening rates in Japan is about 30-40 % [16] . In general, healthconscious women are more likely to visit cancer screening and less likely to smoke. Therefore cancer screening visitors cannot represent an entire Japanese population.
A third limitation is the recall bias of smoking status and smoking dose that derived from self-administered questionnaire. Especially, compared to the case group that could be complemented information by their medical records, the control group might be calculated more inaccurately. The low odds ratio of former smokers in postmenopausal group might be due to this kind of biases.
In a systematic review of breast cancer risk with smoking in Japan [17] , it was concluded that ''tobacco smoking possibly increases the risk of breast cancer in the Japanese population.'' This report included three cohort and eight case-control studies, and there were significant associations only in one cohort and four case-control studies; therefore, a definitive association has not been shown.
The limitation of the case-control study prevents establishment of strong evidence for an increased risk of breast cancer due to smoking based on the NAT2 phenotype. Nonetheless, this study is of some importance, in that it suggests that in Japan, there is little significance in identifying subjects with greater susceptibility to smoking by determining the NAT2 status, as done in Western countries.
Conclusion
Smoking might be associated with a breast cancer risk in most Japanese women, and identification of the NAT2 phenotype may not be of importance in the Japanese population.
